The current status of angiotensin converting enzyme inhibitors in the management of patients with chronic heart failure

M. Packer, M. L. Kukin, G. W. Neuberg, D. J. Pinsky, J. Penn, M. H. Abittan

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Angiotensin converting enzyme (ACE) inhibitors are the only therapeutic agents used in the treatement of chronic heart failure that have been shown to both improve symptoms and prolong life. These agents produce long-term haemodynamic and clinical benefits in about 60-65% of patients. The only reliable means of determining which patients are most likely to respond favourably to treatment is by a therapeutic trial; the response cannot be predicted by demographic factors, pretreatment left ventricular function or plasma renin activity. In addition to their symptomatic benefits, ACE inhibitors reduce the mortality of patients with chronic heart failure, possibly by decreasing ventricular wall stress and decreasing the frequency and complexity of ventricular arrhythmias. The most serious adverse effects of treatment, hypotension, functional renal insufficiency and potassium retention, occur most commonly in patients with the most advanced disease [New York Heart Asssociation (NYHA) class III and IV heart failure] and when efforts are made to block the formation of angiotensin (Ang) II continuously (as with the use of long-acting ACE inhibitors). The unique characteristics of the ACE inhibitors support their use as first-line agents in patients with chronic heart failure.

Original languageEnglish (US)
JournalJournal of Hypertension
Volume7
Issue numberSUPPL. 5
StatePublished - 1989

Fingerprint

Angiotensin-Converting Enzyme Inhibitors
Heart Failure
Proxy
Therapeutics
Left Ventricular Function
Renin
Angiotensin II
Hypotension
Renal Insufficiency
Cardiac Arrhythmias
Potassium
Hemodynamics
Demography
Mortality

ASJC Scopus subject areas

  • Endocrinology
  • Internal Medicine

Cite this

Packer, M., Kukin, M. L., Neuberg, G. W., Pinsky, D. J., Penn, J., & Abittan, M. H. (1989). The current status of angiotensin converting enzyme inhibitors in the management of patients with chronic heart failure. Journal of Hypertension, 7(SUPPL. 5).

The current status of angiotensin converting enzyme inhibitors in the management of patients with chronic heart failure. / Packer, M.; Kukin, M. L.; Neuberg, G. W.; Pinsky, D. J.; Penn, J.; Abittan, M. H.

In: Journal of Hypertension, Vol. 7, No. SUPPL. 5, 1989.

Research output: Contribution to journalArticle

Packer, M, Kukin, ML, Neuberg, GW, Pinsky, DJ, Penn, J & Abittan, MH 1989, 'The current status of angiotensin converting enzyme inhibitors in the management of patients with chronic heart failure', Journal of Hypertension, vol. 7, no. SUPPL. 5.
Packer, M. ; Kukin, M. L. ; Neuberg, G. W. ; Pinsky, D. J. ; Penn, J. ; Abittan, M. H. / The current status of angiotensin converting enzyme inhibitors in the management of patients with chronic heart failure. In: Journal of Hypertension. 1989 ; Vol. 7, No. SUPPL. 5.
@article{dd859b9119f84fa8a9945f258520ec6a,
title = "The current status of angiotensin converting enzyme inhibitors in the management of patients with chronic heart failure",
abstract = "Angiotensin converting enzyme (ACE) inhibitors are the only therapeutic agents used in the treatement of chronic heart failure that have been shown to both improve symptoms and prolong life. These agents produce long-term haemodynamic and clinical benefits in about 60-65{\%} of patients. The only reliable means of determining which patients are most likely to respond favourably to treatment is by a therapeutic trial; the response cannot be predicted by demographic factors, pretreatment left ventricular function or plasma renin activity. In addition to their symptomatic benefits, ACE inhibitors reduce the mortality of patients with chronic heart failure, possibly by decreasing ventricular wall stress and decreasing the frequency and complexity of ventricular arrhythmias. The most serious adverse effects of treatment, hypotension, functional renal insufficiency and potassium retention, occur most commonly in patients with the most advanced disease [New York Heart Asssociation (NYHA) class III and IV heart failure] and when efforts are made to block the formation of angiotensin (Ang) II continuously (as with the use of long-acting ACE inhibitors). The unique characteristics of the ACE inhibitors support their use as first-line agents in patients with chronic heart failure.",
author = "M. Packer and Kukin, {M. L.} and Neuberg, {G. W.} and Pinsky, {D. J.} and J. Penn and Abittan, {M. H.}",
year = "1989",
language = "English (US)",
volume = "7",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins",
number = "SUPPL. 5",

}

TY - JOUR

T1 - The current status of angiotensin converting enzyme inhibitors in the management of patients with chronic heart failure

AU - Packer, M.

AU - Kukin, M. L.

AU - Neuberg, G. W.

AU - Pinsky, D. J.

AU - Penn, J.

AU - Abittan, M. H.

PY - 1989

Y1 - 1989

N2 - Angiotensin converting enzyme (ACE) inhibitors are the only therapeutic agents used in the treatement of chronic heart failure that have been shown to both improve symptoms and prolong life. These agents produce long-term haemodynamic and clinical benefits in about 60-65% of patients. The only reliable means of determining which patients are most likely to respond favourably to treatment is by a therapeutic trial; the response cannot be predicted by demographic factors, pretreatment left ventricular function or plasma renin activity. In addition to their symptomatic benefits, ACE inhibitors reduce the mortality of patients with chronic heart failure, possibly by decreasing ventricular wall stress and decreasing the frequency and complexity of ventricular arrhythmias. The most serious adverse effects of treatment, hypotension, functional renal insufficiency and potassium retention, occur most commonly in patients with the most advanced disease [New York Heart Asssociation (NYHA) class III and IV heart failure] and when efforts are made to block the formation of angiotensin (Ang) II continuously (as with the use of long-acting ACE inhibitors). The unique characteristics of the ACE inhibitors support their use as first-line agents in patients with chronic heart failure.

AB - Angiotensin converting enzyme (ACE) inhibitors are the only therapeutic agents used in the treatement of chronic heart failure that have been shown to both improve symptoms and prolong life. These agents produce long-term haemodynamic and clinical benefits in about 60-65% of patients. The only reliable means of determining which patients are most likely to respond favourably to treatment is by a therapeutic trial; the response cannot be predicted by demographic factors, pretreatment left ventricular function or plasma renin activity. In addition to their symptomatic benefits, ACE inhibitors reduce the mortality of patients with chronic heart failure, possibly by decreasing ventricular wall stress and decreasing the frequency and complexity of ventricular arrhythmias. The most serious adverse effects of treatment, hypotension, functional renal insufficiency and potassium retention, occur most commonly in patients with the most advanced disease [New York Heart Asssociation (NYHA) class III and IV heart failure] and when efforts are made to block the formation of angiotensin (Ang) II continuously (as with the use of long-acting ACE inhibitors). The unique characteristics of the ACE inhibitors support their use as first-line agents in patients with chronic heart failure.

UR - http://www.scopus.com/inward/record.url?scp=0024453902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024453902&partnerID=8YFLogxK

M3 - Article

C2 - 2681605

AN - SCOPUS:0024453902

VL - 7

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - SUPPL. 5

ER -